PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Keensight Capital appoints two Operating Partners

Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments, strengthens its team with the appointment of Dr. Edwin Moses and José Luis Martín as Operating Partners.Edwin Moses’ appointment follows a very successful career as a biopharma entrepreneur, with decades of experience in building successful businesses. Among various achievements, he led the IPO for Ablynx and OAI (Oxford Asymmetry International), companies which he built and managed as CEO.

José Luis Martín was responsible for the development and implementation of corporate strategy at Werfen. For more than thirty years, he played a lead role in transforming the company from a local Spanish distributor to a large multinational company. The innovative firm is now a world leader in the In Vitro Diagnostics market with its products currently sold across more than 100 countries.

Moses, based in Belgium, and José Luis, based in Spain, will be joining Keensight Capital’s team of international Operating Partners. This network, spanning Europe, Asia and the US, connects eminent professionals in the Information Technology/Internet and Healthcare/Wellbeing industries. The Operating Partners share their extensive expertise, vision and international contacts with Keensight Capital’s Investment and Portfolio Performance Teams. The domain-specific Board and Management experience they bring will enable Edwin and José Luis to play an active role in investment sourcing, and value creation for portfolio companies.



Pierre Remy, Managing Partner at Keensight Capital, says: “Following the arrival of Christophe Lavigne in June, we are thrilled to welcome two seasoned professionals such as Dr. Edwin Moses and José Luis Martín in our outstanding network of Operating Partners. Their exceptional track record in expanding companies globally will benefit Keensight as well as the talented managers of our portfolio companies, notably in the Healthcare sector, one of our chosen fields.”
 

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured